Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Logothetis
Eleni Efstathiou
Fil Manuguid
Peter Kirkpatrick

Showing results (71-80 of 476) with videos related to

Pageof 48
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancerNicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, et al.
Nature Reviews. Drug Discovery|August 20, 2004
Tiotropium bromideCynthia Mundy, Peter Kirkpatrick
Nature Reviews. Drug Discovery|May 6, 2004
Tadalafil and vardenafilKatherine Neumeyer, Peter Kirkpatrick
Nature Reviews. Drug Discovery|May 22, 2004
Atomoxetine hydrochlorideMelissa Garland, Peter Kirkpatrick
Nature Reviews. Drug Discovery|June 25, 2004
EfalizumabSylvia Marecki, Peter Kirkpatrick
Nature Reviews. Drug Discovery|February 8, 2003
Fresh from the pipeline. EzetimibeJohn Earl, Peter Kirkpatrick
Expert Opinion on Biological Therapy|April 7, 2009
RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastasesEvangelos Terpos, Eleni Efstathiou, Dimitrios Christoulas, et al.
Biomaterials|January 26, 2019
Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitroClaudia Paindelli, Nora Navone, Christopher J Logothetis, et al.
Journal of the National Cancer Institute|September 16, 2011
Novel therapies for metastatic castrate-resistant prostate cancerFarshid Dayyani, Gary E Gallick, Christopher J Logothetis, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|December 24, 2010
The novel prostate cancer antigen 3 (PCA3) biomarkerAndreas Bourdoumis, Athanasios G Papatsoris, Michael Chrisofos, et al.
Pageof 48

Showing results (71-80 of 476) with videos related to

Sort By:
Pageof 48
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancerNicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, et al.
Nature Reviews. Drug Discovery|August 20, 2004
Tiotropium bromideCynthia Mundy, Peter Kirkpatrick
Nature Reviews. Drug Discovery|May 6, 2004
Tadalafil and vardenafilKatherine Neumeyer, Peter Kirkpatrick
Nature Reviews. Drug Discovery|May 22, 2004
Atomoxetine hydrochlorideMelissa Garland, Peter Kirkpatrick
Nature Reviews. Drug Discovery|June 25, 2004
EfalizumabSylvia Marecki, Peter Kirkpatrick
Nature Reviews. Drug Discovery|February 8, 2003
Fresh from the pipeline. EzetimibeJohn Earl, Peter Kirkpatrick
Expert Opinion on Biological Therapy|April 7, 2009
RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastasesEvangelos Terpos, Eleni Efstathiou, Dimitrios Christoulas, et al.
Biomaterials|January 26, 2019
Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitroClaudia Paindelli, Nora Navone, Christopher J Logothetis, et al.
Journal of the National Cancer Institute|September 16, 2011
Novel therapies for metastatic castrate-resistant prostate cancerFarshid Dayyani, Gary E Gallick, Christopher J Logothetis, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|December 24, 2010
The novel prostate cancer antigen 3 (PCA3) biomarkerAndreas Bourdoumis, Athanasios G Papatsoris, Michael Chrisofos, et al.
Pageof 48